Tempus AI shares surge 13.93% premarket after record $1.1B contract value and strong Q4 sales growth with pharma partnerships.

Tempus AI surged 13.93% in premarket trading following multiple positive developments. The company announced record total contract value (TCV) exceeding $1.1 billion and signed data agreements with over 70 clients, including major pharmaceutical firms like AstraZeneca and Pfizer. Additionally, collaborations with Northwestern Medicine and NYU Langone Health to expand genomic testing in oncology underscored its growing influence in precision medicine. Preliminary Q4 data showed diagnostics revenue more than doubling to $266 million, while full-year data and application revenue hit $316 million, reflecting 31% year-over-year growth. These milestones, coupled with CEO Eric Lefkofsky’s emphasis on 2026 growth potential, reinforced investor confidence in Tempus’s market expansion and financial momentum.